SCHEMBL24259698

SCHEMBL24259698

NCCCCCc1nc(C2CC2)no1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.41
MEN1 O00255 3/20 0.36
KMT2A Q03164 3/20 0.36
HTR1A P08908 1/20 0.36
HTR2C P28335 1/20 0.36
CA1 P00915 2/20 0.36
CA2 P00918 2/20 0.36
CA9 Q16790 2/20 0.36
POLB P06746 1/20 0.36
AKR1C4 P17516 1/20 0.35
AKR1C3 P42330 1/20 0.35
AKR1C2 P52895 1/20 0.35
AKR1C1 Q04828 1/20 0.35
GAA P10253 1/20 0.34
HSD11B1 P28845 1/20 0.33
CA12 O43570 1/20 0.33
LMNA P02545 1/20 0.33
ALOX5AP P20292 2/20 0.32
FEN1 P39748 2/20 0.32
AOC3 Q16853 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1786515 0.86 L3MBTL1 (0.44) L3MBTL1MEN1KMT2AHTR1AHTR2C
Hydrochloric Acid SCHEMBL3948870 0.84 L3MBTL1 (0.43) L3MBTL1MEN1KMT2AHTR1AHTR2C
SCHEMBL440391 0.78 L3MBTL1 (0.43) L3MBTL1MEN1KMT2AHTR1AHTR2C
SCHEMBL24258740 0.78 L3MBTL1 (0.39) L3MBTL1MEN1KMT2ACA1CA2
SCHEMBL24259025 0.76 POLB (0.41) L3MBTL1MEN1KMT2ACA1CA2
SCHEMBL24258804 0.75 AKR1C4 (0.44) L3MBTL1MEN1KMT2APOLBAKR1C4
SCHEMBL24092039 0.73 POLB (0.40) L3MBTL1MEN1KMT2APOLBAKR1C4
SCHEMBL24258686 0.72 MIF (0.42) L3MBTL1AKR1C4AKR1C3AKR1C2AKR1C1
SCHEMBL15912643 0.71 L3MBTL1 (0.47) L3MBTL1MEN1KMT2ACA1CA2
SCHEMBL10120678 0.71 POLB (0.47) L3MBTL1MEN1KMT2ACA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11713312-B2 Substituted bicyclic compounds as farnesoid X receptor modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2023-08-01 US disclosed
US-20220135550-A1 SUBSTITUTED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS BRISTOL MYERS SQUIBB CO (US) 2022-05-05 US disclosed
US-11254663-B2 Substituted bicyclic compounds as farnesoid X receptor modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2022-02-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220135550-A1 SUBSTITUTED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS FXR1, NR1H4, FXR2 L3MBTL1 4270/4885MEN1 3478/4885KMT2A 4497/4885
US-11254663-B2 Substituted bicyclic compounds as farnesoid X receptor modulators FXR1, NR1H4, FXR2 L3MBTL1 4270/4885MEN1 3478/4885KMT2A 4497/4885
US-11713312-B2 Substituted bicyclic compounds as farnesoid X receptor modulators FXR1, NR1H4, FXR2 L3MBTL1 4270/4885MEN1 3478/4885KMT2A 4497/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.